
Ep.378: An Enigmacursor wrapped in a riddle inside a mystery?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
a day ago
- News.com.au
‘Dark spots': COVID jab tied to rare health symptom
New research is calling for further study on a possible link between COVID-19 jabs and long-term vision issues. While vaccines have been vital in fighting the pandemic, emerging data could mean we're not out of the woods yet. Between January 2021 and January 2023, 20 peer-reviewed studies looked into eye problems reported by 243 people aged 18 to 84 who had received COVID-19 vaccines. Almost half of these patients - 42 per cent - had the Pfizer-BioNTech jab, which was the main vaccine rolled out in Australia, the USA, the UK, and much of Europe. What jumps out is inflammation. Nearly half of the patients reported experiencing ocular inflammatory conditions like uveitis, an irritation deep inside the eye. Another 24 per cent were said to have suffered optic neuritis, a swelling of the optic nerve that can cause pain and threaten vision. Herpetic eye disease, caused by the herpes virus attacking the eye, showed up in 14 per cent of cases, triggering redness, pain, and discomfort. About 10 per cent documented retinal circulation issues - blockages in the eye's arteries or veins that can trigger sudden vision loss. And there were also a few rare cases where patients were noted to exhibit retina-related problems causing 'dark spots' or 'blind patches'. But the most notable observations come from a recent Turkish study that tracked 64 patients before and after their two mRNA vaccine doses. Using detailed eye scans, researchers found an 8 per cent drop in the cornea's endothelial cell count - the cells responsible for keeping the cornea clear. These cells don't regenerate, and losing too many can permanently impair vision. To put that into perspective, healthy adults usually have between 2000 and 3000 of these cells per square millimetre. After vaccination, the average dropped from 2597 to 2378. While these numbers are still considered safe for most, the decline could be a warning sign for people with pre-existing eye conditions or those who have had eye surgeries like LASIK, cataract removal, or corneal transplants. Researchers also noted that corneas thickened by around 2 per cent after vaccination - a sign of possible swelling. The honeycomb shape of the endothelial cells became distorted, and the size differences between individual cells increased, which are both signs of cellular stress. Though none of the study participants reported immediate vision problems, experts warn that long-term structural changes to the cornea could lead to lasting damage, especially in vulnerable patients. Dr Fatma Sümer and Sevgi SubaÅŸi, authors of the study published in Ophthalmic Epidemiology, stressed the need for careful observation: 'The endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.' According to Healthline, eye complications after vaccination are rare and appear to be driven by an overactive immune response. Symptoms can include blurred vision, light sensitivity, redness, eye pain, shingles around the eye, or reactivated herpes infections. In even rarer cases, the immune system may reject a previously transplanted cornea, risking vision loss and graft failure. This means the transplanted cornea loses its clarity and function, leading to impaired vision and the potential need for further treatment or surgery. These findings are not conclusive, and experts do not advise people to skip their COVID vaccine shots — far from it. But they are urging doctors and patients to not ignore these subtle warning signs. Those who have had prior eye surgery, suffer from chronic eye disease, or notice persistent blurry vision after vaccination are advised to be checked, because even small changes inside your eyes can have big consequences down the road According to safety reports from the Therapeutic Goods Administration (TGA), 'vaccination is the most effective way to reduce deaths and severe illness from infection.' Like all medicines, the TGA notes, 'COVID-19 vaccines may cause some side effects. 'The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills.' The TGA closely monitors reports of adverse events to the COVID-19 vaccines and emphasises that 'the protective benefits of vaccination far outweigh the potential risks.'

News.com.au
2 days ago
- News.com.au
Paralysed woman writes her name for the first time in 20 years after having Elon Musk Neuralink chip implant surgery
A woman paralysed since 2005 has written her name for the first time in two decades thanks to Elon Musk. Audrey Crews became the first woman in the world to undergo surgery earlier this month receiving Mr Musk's Neuralink chip implant, allowing her to control a computer with her mind. Ms Crews recently took to X to show the world how she was able to select a coloured cursor on screen and sign her name through telepathy. She showed off how she could also draw pictures, scroll with a mouse and use a keyboard just by thinking. 'I tried writing my name for the first time in 20 years. I'm working on it. Lol,' she said. 'I am the first woman in the world to do this.' Ms Crews was left a quadriplegic at age 16 following a car accident that left the vertebrae in her neck permanently damaged. By 2016, tech billionaire Musk co-founded Neuralink with expert in neuroscience in hopes of using AI tech to treat brain disorders. Three years later he revealed the N1 chip, which is placed on the brain to translate electrical signals into tasks. Ms Crews is just the ninth recipient. She underwent surgery at the University of Miami Health Centre where surgeons place over 100 threads, thinner than human hair into her motor cortex after drilling through her skull. The implant, roughly the size of a 10 cent coin, sends those signals to a linked computer or smartphone with Neuralink's software via Bluetooth, allowing patients with paralysis or neurological conditions to communicate digitally. 'Imagine your pointer finger is left click and the cursor is with your wrist, without physically doing it. Just a normal day using telepathy,' she said. Ms Crews has also started taking requests of what to draw next, recently sketching a cat, a sun and a tree after being asked by X users. She's also able to play simulation games testing her accuracy and speed by having her cursor track points on the screen as they change. Mr Musk even replied to a post about Ms Crews' story. 'She is controlling her computer just by thinking. Most people don't realise this is possible,' he said. While the technology won't allow her to regain movement of her limbs, the advancement has so far impressed Ms Crews who hopes to make the most of it by writing a book about her experiences. The chip is powered by a small battery that charges wirelessly. Asked if she ever imagined being able to communicate in such a way again, Ms Crews had one response: 'Not in all my wildest dreams, but the future is here.'

The Australian
3 days ago
- The Australian
Study backs Alterity tool for tracking MSA
Special Report: Alterity Therapeutics has unveiled promising new research showing its novel brain imaging tool could play a key role in diagnosing and tracking Multiple System Atrophy (MSA), a rare and aggressive neurodegenerative disease. Quality peer-reviewed publication highlights use of Alterity's MSA Atrophy Index developed to diagnose and track MSA disease progression Tool helps pinpoint changes in brain over time, making it easier to detect disease progression and assess treatments MSA Atrophy Index developed as part of Alterity's bioMUSE natural history study with Vanderbilt University Medical Center The peer-reviewed study, published in peer-reviewed journal Annals of Clinical and Translational Neurology, highlights a new MRI-based measure called the MSA Atrophy Index (MSA-AI) – developed as part of Alterity Therapeutics' (ASX:ATH) bioMUSE natural history study. Using artificial intelligence (AI), the tool helps pinpoint changes in the brain over time, making it easier to detect disease progression and assess how well treatments are working. MSA-AI offers a standardised way to measure brain shrinkage in regions affected by the disease, regardless of the subtype. This makes it a useful tool for both diagnosing patients earlier and improving how clinical trial participants are selected. The study combined data from both early-stage and more advanced MSA patients, capturing a wide range of disease severity. The approach has helped researchers confirm that the MSA-AI could reliably track changes in brain volume over time and differentiate MSA from other similar neurological conditions like Parkinson's disease and Lewy body dementia. Importantly, lower MSA-AI scores were linked to more severe symptoms and greater disease progression over 12 months, highlighting the tool's potential value in future clinical trials and patient care. About the bioMUSE study Titled Biomarkers of Progression in Multiple System Atrophy (bioMUSE), the natural history study tracks the progression of individuals with MSA, a Parkinsonian disorder without an approved therapy. The study was conducted in collaboration with Vanderbilt University Medical Center in the US under the direction of Daniel Claassen M.D, M.S, professor of neurology and principal investigator. Alterity noted that natural history studies were important for characterising disease progression in selected patient populations. Insights into early-stage MSA The company said the study had provided rich data for optimising the design of its randomised ATH434-201 phase II clinical trial and had enrolled ~20 individuals with clinically probable or clinically established MSA. The bioMUSE study continues to provide critical insights into early-stage MSA, helping select biomarkers and track disease progression in patients like those in its phase II trial. 'This research used state-of-the-art technology employed in the bioMUSE study that goes above and beyond traditional MRI methods for assessing brain volume in patients with MSA,' Alterity's US-based CEO Dr David Stamler said. 'Based on the creativity and technical skill of our colleagues at Vanderbilt University Medical Center, we now have superior tools for diagnosing MSA and tracking brain atrophy over time. 'Importantly, we observed that statistically significant reductions in brain volume over 12 months correlated with clinical worsening of the disease.' Stamler said the results underscore importance of using advanced neuroimaging methods and analytical tools in evaluating MSA, which Alterity implemented in its phase II clinical program. 'While previous MRI studies have reported brain volume reductions in MSA-affected brain regions, tracking these changes reliably has been challenging,' he said. Stamler said development of the MSA Atrophy Index can enhance the understanding of MSA progression and provide support for using brain atrophy markers for evaluation of disease-modifying therapies. 'These tools offer potential applications in diagnosis, staging, and monitoring of disease severity, contributing to more personalised care in MSA,' he said. 'We look forward to leveraging this invaluable technology for patient selection and disease progression in our phase III clinical trial.' This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.